Your session is about to expire
← Back to Search
Other
ZEN003694 Continuation for Prostate Cancer
Phase 1 & 2
Waitlist Available
Research Sponsored by Zenith Epigenetics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial continues to provide ZEN003694 to patients who have already shown improvement from it in an earlier study. The medication helps by changing certain body functions related to their condition. Patients must have been part of an earlier study with this medication to join this continuation trial.
Who is the study for?
This trial is for prostate cancer patients who saw benefits from a previous ZEN003694 study. They should be in good physical condition (ECOG status of 0 or 1) and have handled the drug well before. Participants must start this follow-up within two weeks after their last dose in the original trial, unless given more time by the sponsor.
What is being tested?
The study continues treatment with ZEN003694 for those who benefited previously, alongside Enzalutamide, an established prostate cancer medication. The aim is to see if ongoing treatment maintains or improves patient outcomes.
What are the potential side effects?
While specific side effects are not listed here, participants must have tolerated ZEN003694 well during prior trials to join this continuation protocol. Side effects may include those experienced earlier plus any associated with Enzalutamide.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2019 Phase 1 & 2 trial • 75 Patients • NCT0271195658%
Visual impairment
52%
Nausea
42%
Fatigue
32%
Decreased appetite
32%
Dysgeusia
19%
Thrombocytopenia
16%
Diarrhea
10%
Weight decreased
10%
Taste disorder
10%
Photosensitivity reaction
10%
Constipation
10%
Photopsia
10%
Vomiting
10%
Dizziness
10%
Blood creatinine increased
3%
Intervertebral discitis
3%
Acute kidney injury
3%
Musculoskeletal pain
3%
Myocardial ischaemia
3%
Spinal cord compression
3%
Rash maculopapular
100%
80%
60%
40%
20%
0%
Study treatment Arm
DE/DC A+B 96 mg ZEN003694 + Enzalutamide
DE A+B 36 mg ZEN003694 + Enzalutamide
DE/DC A+B 48 mg ZEN003694 + Enzalutamide
DE A+B 60 mg ZEN003694 + Enzalutamide
DE A+B 72 mg ZEN003694 + Enzalutamide
DE A+B 120 mg ZEN003694 + Enzalutamide
DE A+B 144 mg ZEN003694 + Enzalutamide
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Experimental: ZEN003694 in Combination with EnzalutamideExperimental Treatment2 Interventions
Patients who have completed participation in their original ZEN003694-002 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in combination with enzalutamide
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enzalutamide
2014
Completed Phase 4
~3820
ZEN003694
2016
Completed Phase 2
~120
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for prostate cancer include androgen deprivation therapy (ADT), androgen receptor signaling inhibitors, and BET inhibitors like ZEN003694. ADT reduces androgen levels, which prostate cancer cells need to grow.
Androgen receptor signaling inhibitors, such as enzalutamide and abiraterone, block the androgen receptor or inhibit androgen production, preventing cancer cell proliferation. BET inhibitors target proteins that regulate gene expression, including genes involved in cancer growth and survival.
Understanding these mechanisms helps in selecting treatments tailored to the cancer's specific characteristics and resistance patterns.
Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.
Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.
Find a Location
Who is running the clinical trial?
Zenith EpigeneticsLead Sponsor
9 Previous Clinical Trials
546 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Experimental: ZEN003694 in Combination with Enzalutamide
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger